{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:57:21Z","timestamp":1776859041097,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ferrer Internacional, S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There are limited data in the literature on the indirect costs associated with skin and soft tissue infections (SSTIs) in the pediatric population. This study aimed to conduct a systematic review of the indirect costs associated with SSTIs in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The search was conducted in PubMed, SCOPUS, and Web of Science up to January 2020. Thirteen search strategies were designed combining MeSH terms and free terms. SSTIs were defined as bacterial or viral infections, dermatomycoses, and parasitic infestations. Only primary studies were included. All analyzed costs were converted to 2020 Euros.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirteen of the identified publications presented indirect costs of SSTIs in children and were conducted in Argentina, Australia, Brazil, Hungary, New Zealand, Poland, Spain, Taiwan, and the USA. Nine studies described indirect costs associated with infection of <jats:italic>Varicella-zoster virus<\/jats:italic>: lost workdays by outpatient caregivers ranged from 0.27 to 7.8, and up to 6.14 if caring for inpatients; total productivity losses ranged from \u20ac1.16 to \u20ac257.46 per patient. Three studies reported indirect costs associated with acute bacterial SSTIs (community-associated methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic>) in children: total productivity losses ranged from \u20ac1,814.39 to \u20ac8,224.06 per patient, based on impetigo, cellulitis, and folliculitis. One study of parasitic infestations (<jats:italic>Pediculus humanus capitis<\/jats:italic>) reported total indirect costs per patient\u00a0of \u20ac68.57 (formal care)\u00a0plus \u20ac21.41 due to time lost by parents in purchasing treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The economic burden of SSTIs is highly relevant but underestimated due to the lack of studies reporting indirect costs. Further cost studies will allow a better understanding of the magnitude of the financial burden of the disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-021-07189-3","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T08:02:31Z","timestamp":1639209751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Indirect costs associated with skin infectious disease in children: a systematic review"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-5968","authenticated-orcid":false,"given":"Irene","family":"Lizano-D\u00edez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Naharro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilonka","family":"Zsolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"issue":"10258","key":"7189_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9.","journal-title":"Lancet"},{"issue":"2","key":"7189_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.suc.2008.09.006","volume":"89","author":"AK May","year":"2009","unstructured":"May AK. Skin and soft tissue infections. Surg Clin North Am. 2009;89(2):403\u201320, viii. https:\/\/doi.org\/10.1016\/j.suc.2008.09.006.","journal-title":"Surg Clin North Am"},{"issue":"1","key":"7189_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13017-018-0219-9","volume":"13","author":"M Sartelli","year":"2018","unstructured":"Sartelli M, Guirao X, Hardcastle TC, Kluger Y, Boermeester MA, Ra\u015fa K, et al. 2018 WSES\/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg. 2018;13(1):58. https:\/\/doi.org\/10.1186\/s13017-018-0219-9.","journal-title":"World J Emerg Surg"},{"issue":"10","key":"7189_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1586\/erv.12.93","volume":"11","author":"S Esposito","year":"2012","unstructured":"Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines. 2012;11(10):1199\u2013209. https:\/\/doi.org\/10.1586\/erv.12.93.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"7189_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","volume":"48","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Amin A, Ford WT Jr, Finley R, Kaye KS, Nguyen HH, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508\u201319. https:\/\/doi.org\/10.1016\/j.jemermed.2014.12.001.","journal-title":"J Emerg Med"},{"issue":"12","key":"7189_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/smj.0000000000000032","volume":"106","author":"TN Wright","year":"2013","unstructured":"Wright TN, Gilligan L, Zhurbich O, Davenport DL, Draus JM Jr. Minimally invasive drainage of subcutaneous abscesses reduces hospital cost and length of stay. South Med J. 2013;106(12):689\u201392. https:\/\/doi.org\/10.1097\/smj.0000000000000032.","journal-title":"South Med J"},{"issue":"8","key":"7189_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jama.279.8.593","volume":"279","author":"BC Herold","year":"1998","unstructured":"Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279(8):593\u20138. https:\/\/doi.org\/10.1001\/jama.279.8.593.","journal-title":"JAMA"},{"issue":"6","key":"7189_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1469-0691.2012.03914.x","volume":"19","author":"BY Lee","year":"2013","unstructured":"Lee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2013;19(6):528\u201336. https:\/\/doi.org\/10.1111\/j.1469-0691.2012.03914.x.","journal-title":"Clin Microbiol Infect"},{"key":"7189_CR9","first-page":"1","volume":"1","author":"EB Chahine","year":"2015","unstructured":"Chahine EB, Sucher AJ. Skin and soft tissue infections. PSAP. 2015;1:1\u201327.","journal-title":"PSAP"},{"issue":"23","key":"7189_CR10","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1016\/S0264-410X(03)00264-0","volume":"21","author":"J D\u00edez-Domingo","year":"2003","unstructured":"D\u00edez-Domingo J, Aristegui J, Calbo F, Gonzalez-Hachero J, Moraga F, Pe\u00f1a Guitian J, et al. Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study. Vaccine. 2003;21(23):3236\u20139. https:\/\/doi.org\/10.1016\/S0264-410X(03)00264-0.","journal-title":"Vaccine"},{"issue":"10","key":"7189_CR11","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa0905471","volume":"362","author":"O Chosidow","year":"2010","unstructured":"Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010;362(10):896\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa0905471.","journal-title":"N Engl J Med"},{"issue":"9","key":"7189_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s10096-012-1575-0","volume":"31","author":"H Feldmeier","year":"2012","unstructured":"Feldmeier H. Pediculosis capitis: new insights into epidemiology, diagnosis and treatment. Eur J Clin Microbiol Infect Dis. 2012;31(9):2105\u201310. https:\/\/doi.org\/10.1007\/s10096-012-1575-0.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"7189_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1542\/peds.110.3.638","volume":"110","author":"BL Frankowski","year":"2002","unstructured":"Frankowski BL, Weiner LB, Taras HL, Frankowski BL, McGrath JW, Mears C, et al. Head lice. Pediatrics. 2002;110(3):638\u201343.","journal-title":"Pediatrics"},{"issue":"9","key":"7189_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/11313740-000000000-00000","volume":"27","author":"I Gur","year":"2009","unstructured":"Gur I, Schneeweiss R. Head lice treatments and school policies in the US in an era of emerging resistance: a cost-effectiveness analysis. Pharmacoeconomics. 2009;27(9):725\u201334. https:\/\/doi.org\/10.2165\/11313740-000000000-00000.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"7189_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/000992280404300603","volume":"43","author":"RC Hansen","year":"2004","unstructured":"Hansen RC, O'Haver J. Economic considerations associated with Pediculus humanus capitis infestation. Clin Pediatr (Phila). 2004;43(6):523\u20137. https:\/\/doi.org\/10.1177\/000992280404300603.","journal-title":"Clin Pediatr (Phila)"},{"issue":"4","key":"7189_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","volume":"32","author":"M Krol","year":"2014","unstructured":"Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32(4):335\u201344. https:\/\/doi.org\/10.1007\/s40273-014-0132-3.","journal-title":"Pharmacoeconomics"},{"key":"7189_CR17","unstructured":"CRD\u2019s guidance for undertaking reviews in health care: Centre for Reviews and Disseminations. University of York. 2009. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 19 Nov 2021. [internet]."},{"issue":"4","key":"7189_CR18","doi-asserted-by":"publisher","first-page":"W-65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W-65\u201394.","journal-title":"Ann Intern Med"},{"issue":"7023","key":"7189_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"DL Sackett","year":"1996","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71\u20132. https:\/\/doi.org\/10.1136\/bmj.312.7023.71.","journal-title":"BMJ"},{"key":"7189_CR20","unstructured":"Public Health Wales Observatory Evidence Service. Questions to assist with the critical appraisal of a cost of illness\/ risk factor analysis Wales: public health Wales. Public Health Wales. 2014. https:\/\/www2.nphs.wales.nhs.uk. Accessed 19 Nov 2021. [internet]."},{"issue":"1","key":"7189_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence Policy J Rese Debate Pract. 2010;6(1):51\u20139. https:\/\/doi.org\/10.1332\/174426410X482999.","journal-title":"Evidence Policy J Rese Debate Pract"},{"key":"7189_CR22","doi-asserted-by":"publisher","unstructured":"OECD. Inflation (CPI) (indicator). 2020, 2020. https:\/\/doi.org\/10.1787\/eee82e6e-en. Accessed on 23 Feb 2020. [internet].","DOI":"10.1787\/eee82e6e-en"},{"key":"7189_CR23","unstructured":"The National Institute for Health and Care Excellence (NICE). Appendix 4: Quality assessment for Case series. https:\/\/www.nice.org.uk\/guidance\/cg3\/documents\/appendix-4-quality-of-case-series-form2. Accessed 17 Jun 2020. [internet]."},{"issue":"4","key":"7189_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","volume":"16","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, van Gils PF, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):513\u201323. https:\/\/doi.org\/10.1586\/14737167.2015.1103185.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"25\u201326","key":"7189_CR25","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1016\/s0264-410x(03)00270-6","volume":"21","author":"HC Hsu","year":"2003","unstructured":"Hsu HC, Lin RS, Tung TH, Chen TH. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine. 2003;21(25\u201326):3982\u20137. https:\/\/doi.org\/10.1016\/s0264-410x(03)00270-6.","journal-title":"Vaccine"},{"issue":"49","key":"7189_CR26","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1016\/j.vaccine.2008.07.021","volume":"26","author":"J Valentim","year":"2008","unstructured":"Valentim J, Sartori AM, de Soarez PC, Amaku M, Azevedo RS, Novaes HM. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine. 2008;26(49):6281\u201391. https:\/\/doi.org\/10.1016\/j.vaccine.2008.07.021.","journal-title":"Vaccine"},{"issue":"6","key":"7189_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/s0277-9536(99)00115-x","volume":"49","author":"P Scuffham","year":"1999","unstructured":"Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med. 1999;49(6):763\u201379. https:\/\/doi.org\/10.1016\/s0277-9536(99)00115-x.","journal-title":"Soc Sci Med"},{"issue":"2","key":"7189_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1542\/peds.89.2.210","volume":"89","author":"TD Rice","year":"1992","unstructured":"Rice TD, Duggan AK, DeAngelis C. Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. Pediatrics. 1992;89(2):210\u20134.","journal-title":"Pediatrics"},{"issue":"1","key":"7189_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1440-1754.1998.00146.x","volume":"34","author":"M Ferson","year":"1998","unstructured":"Ferson M, Shen W, Stark A. Direct and indirect costs of chickenpox in young children. J Paediatr Child Health. 1998;34(1):18\u201321. https:\/\/doi.org\/10.1046\/j.1440-1754.1998.00146.x.","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"7189_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/13696998.2018.1431919","volume":"21","author":"N Giglio","year":"2018","unstructured":"Giglio N, Monsanto H, Rampakakis E, Yang HK, Kuter BJ, Wolfson LJ. Economic burden of varicella in children 1-12 years of age in Argentina, 2009-2014. J Med Econ. 2018;21(4):416\u201324. https:\/\/doi.org\/10.1080\/13696998.2018.1431919.","journal-title":"J Med Econ"},{"issue":"3","key":"7189_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00006454-199403000-00001","volume":"13","author":"TA Lieu","year":"1994","unstructured":"Lieu TA, Black SB, Rieser N, Ray P, Lewis EM, Shinefield HR. The cost of childhood chickenpox: parents' perspective. Pediatr Infect Dis J. 1994;13(3):173\u20137. https:\/\/doi.org\/10.1097\/00006454-199403000-00001.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"7189_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12889-018-5298-8","volume":"18","author":"J Wysocki","year":"2018","unstructured":"Wysocki J, Malecka I, Stryczynska-Kazubska J, Rampakakis E, Kuter B, Wolfson LJ. Varicella in Poland: economic burden in children 1-12 years of age in Poland, 2010-2015. BMC Public Health. 2018;18(1):410. https:\/\/doi.org\/10.1186\/s12889-018-5298-8.","journal-title":"BMC Public Health"},{"issue":"1","key":"7189_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12879-017-2575-6","volume":"17","author":"Z Meszner","year":"2017","unstructured":"Meszner Z, Molnar Z, Rampakakis E, Yang HK, Kuter BJ, Wolfson LJ. Economic burden of varicella in children 1-12 years of age in Hungary, 2011-2015. BMC Infect Dis. 2017;17(1):495. https:\/\/doi.org\/10.1186\/s12879-017-2575-6.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"7189_CR34","first-page":"409","volume":"6","author":"KY Mumcuoglu","year":"2007","unstructured":"Mumcuoglu KY, Barker SC, Burgess I, Combescot-Lang C, Dalgleish RC, Larsen KS, et al. International guidelines for effective control of head louse infestations. J Drugs Dermatolog JDD. 2007;6(4):409\u201314.","journal-title":"J Drugs Dermatolog JDD"},{"issue":"1","key":"7189_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4161\/hv.36160","volume":"11","author":"D Panatto","year":"2015","unstructured":"Panatto D, Bragazzi NL, Rizzitelli E, Bonanni P, Boccalini S, Icardi G, et al. Evaluation of the economic burden of herpes zoster (HZ) infection. Hum Vaccin Immunother. 2015;11(1):245\u201362. https:\/\/doi.org\/10.4161\/hv.36160.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"7189_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/INF.0b013e31826ff3a5","volume":"31","author":"A Bardach","year":"2012","unstructured":"Bardach A, Cafferata ML, Klein K, Cormick G, Gibbons L, Ruvinsky S. Incidence and use of resources for chickenpox and herpes zoster in Latin America and the Caribbean--a systematic review and meta-analysis. Pediatr Infect Dis J. 2012;31(12):1263\u20138. https:\/\/doi.org\/10.1097\/INF.0b013e31826ff3a5.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"7189_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14760584.2019.1594781","volume":"18","author":"AEN Goh","year":"2019","unstructured":"Goh AEN, Choi EH, Chokephaibulkit K, Choudhury J, Kuter B, Lee PI, et al. Burden of varicella in the Asia-Pacific region: a systematic literature review. Expert Rev Vaccines. 2019;18(5):475\u201393. https:\/\/doi.org\/10.1080\/14760584.2019.1594781.","journal-title":"Expert Rev Vaccines"},{"issue":"9544","key":"7189_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","volume":"368","author":"U Heininger","year":"2006","unstructured":"Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(06)69561-5.","journal-title":"Lancet"},{"issue":"8","key":"7189_CR39","doi-asserted-by":"publisher","first-page":"e0136789-e","DOI":"10.1371\/journal.pone.0136789","volume":"10","author":"AC Bowen","year":"2015","unstructured":"Bowen AC, Mah\u00e9 A, Hay RJ, Andrews RM, Steer AC, Tong SYC, et al. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS One. 2015;10(8):e0136789-e. https:\/\/doi.org\/10.1371\/journal.pone.0136789.","journal-title":"PLoS One"},{"key":"7189_CR40","unstructured":"INE. Instituto Nacional de Estad\u00edstica. https:\/\/www.ine.es\/index.htm. Accessed 17 Jun 2020. [internet]."},{"issue":"3","key":"7189_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.idc.2015.05.007","volume":"29","author":"CB Creech","year":"2015","unstructured":"Creech CB, Al-Zubeidi DN, Fritz SA. Prevention of recurrent staphylococcal skin infections. Infect Dis Clin N Am. 2015;29(3):429\u201364. https:\/\/doi.org\/10.1016\/j.idc.2015.05.007.","journal-title":"Infect Dis Clin N Am"},{"key":"7189_CR42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.biopha.2018.10.131","volume":"109","author":"S Khoshnood","year":"2019","unstructured":"Khoshnood S, Heidary M, Asadi A, Soleimani S, Motahar M, Savari M, et al. A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus. Biomed Pharmacother. 2019;109:1809\u201318. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.131.","journal-title":"Biomed Pharmacother"},{"key":"7189_CR43","volume-title":"Human lice: their prevalence, control and resistance to insecticides: a review 1985\u20131997","author":"NG Gratz","year":"1997","unstructured":"Gratz NG, Organization WH. Human lice: their prevalence, control and resistance to insecticides: a review 1985\u20131997. Geneva: World Health Organization; 1997."},{"key":"7189_CR44","doi-asserted-by":"publisher","first-page":"S544","DOI":"10.1016\/j.jval.2020.08.836","volume":"23","author":"I Lizano-D\u00edez","year":"2020","unstructured":"Lizano-D\u00edez I, Garcia J, Zsolt I. Impact of acute bacterial skin infections in quality of life: a neglected area. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020. Value Health. 2020;23:S544. https:\/\/doi.org\/10.1016\/j.jval.2020.08.836.","journal-title":"Value Health"},{"issue":"S1","key":"7189_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/pde.14594","volume":"38","author":"I Lizano-D\u00edez","year":"2021","unstructured":"Lizano-D\u00edez I, Garcia J, Zsolt I. Quality of life scales in pediatric dermatology: a systematic literature review. Pediatr Dermatol. 2021;38(S1):65\u201391. https:\/\/doi.org\/10.1111\/pde.14594.","journal-title":"Pediatr Dermatol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07189-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-021-07189-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07189-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T04:52:10Z","timestamp":1643259130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-07189-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7189"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-07189-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Additional file 1 was replaced with a clean version.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ILD, JN and IZ are employees at Ferrer Internacional, S.A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1325"}}